News

Syntrix Clinical Trial of Omnitram Succeeds on Primary Endpoints

Syntrix announced that the Phase 1B study investigating Omnitram for pain in healthy subjects met its primary endpoints for pharmacokinetics, safety, and analgesia.  The study was performed with Syntrix collaborators at PRA International and the IIT Research Institute.  The study was funded by a $1.8 million grant from the National Institute on Drug Abuse (NIDA) […]

Syntrix Publication in Bioorganic & Medicinal Chemistry Letters

Congratulations to Syntrix scientists on their latest publication, which appeared in the journal Bioorganic & Medicinal Chemistry Letters.  Abstract: Blockade of undesired neutrophil migration to sites of inflammation remains an area of substantial pharmaceutical interest.  To effect this blockade, a validated therapeutic target is antagonism of the chemokine receptor CXCR2.  Herein we report the discovery […]

Syntrix Wins U.S. Patent 9,000,142: Photocleavable Sense-Antisense Complex

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventor:  Zebala; John A. (Sammamish, WA) Abstract:  There is disclosed a photocleavable sense-antisense nucleobase polymer complex capable of modulating gene expression comprising an unnatural antisense nucleobase polymer that targets an mRNA, and a photocleavable sense nucleobase polymer noncovalently […]

Syntrix Wins U.S. Patent 8,993,541: Aminopyrimidine Carboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); Zebala, John A. (Sammamish, WA); and Schuler, Aaron D. (Auburn, WA).  Abstract: There are disclosed aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyrimidinecarboxamides compounds. More specifically, […]

Syntrix Wins U.S. Patent 8,981,106: Pyrimidinecarboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); and Zebala, John A. (Sammamish, WA).  Abstract: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there […]

Syntrix Wins U.S. Patent 8,969,365: Thiopyrimidinecarboxamides as CXCR1/2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); Zebala, John A. (Sammamish, WA); and Schuler, Aaron D. (Auburn, WA).  Abstract: There is disclosed a pyrimidinecarboxamide compound useful as a pharmaceutical agent, synthetic processes, and pharmaceutical compositions which include the pyrimidinecarboxamide […]

Syntrix Publication in Journal of Medicinal Chemistry

Congratulations to Syntrix scientists on their latest publication, which appeared in the ACS Journal of Medicinal Chemistry.  Abstract: The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis.  In inflammation, they activate and recruit polymorphonuclear cells (PMNs) through binding of the chemokines CXCL1 (CXCR1) and CXCL8 (CXCR1 and CXCR2).  […]

Syntrix Receives $1.725M Grant to Conduct a Phase II Clinical Trial for the treatment of Psoriasis with (L/D)-Aminopterin

Congratulations to Syntrix scientists on their new grant for $1.725M from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH).  The project title is “Efficacy and Resistance Mechanisms of (L/D)-Aminopterin in Psoriasis.”  Here is the public health relevance from the proposal:  “Psoriasis is a chronic scaly and inflammatory […]

Syntrix Featured in the NIH Innovation Zone at 2014 Bio International Convention in San Diego, CA

Syntrix was selected by the NIH to host a kiosk in the Innovation Zone, an area dedicated to showcasing Small Business Innovation Research (SBIR) grantees.  In addition, Syntrix was granted an additional opportunity to present their innovative research at the NIH Booth located in Hall A of the Discovery Zone.  The Syntrix presentation featured SX-682, […]

Syntrix Wins U.S. Patent 8,748,623: Pyridinecarboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); and Zebala, John A. (Sammamish, WA).  Abstract: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there […]